Balancing Efficacy, Safety, and Cost in Formulary Decisions for Cell and Gene Therapies: Clayton Irvine, PharmD, MBA, MS

Clayton Irvine, PharmD, MBA, MS, emphasized that optimizing value-based access to cell and gene therapies requires standardized care protocols, coordinated transitions between care settings, careful evaluation of prior authorization and financial assistance options, and formulary decisions that balance clinical outcomes with both direct and indirect costs to patients and institutions.